Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Filing Amendment Overview
INCY logo

Incyte's Revenues Climb 11% to $3.87 Billion on Jakafi Strength

INCY10-KFiling Date: 2/16/2024
Incyte Corporation
Description

What this story covers

Incyte's 2023 10-K amendment fixes a governance exhibit without altering financials. Revenues rose 11% to $3.87B, driven by Jakafi ($2.6B) and Opzelura ($333M) growth. Robust $2.46B cash supports $1.1B R&D amid pipeline risks and 2027 patent cliff.

Story snapshot

CompanyIncyte Corporation
TickerINCY
VariantStandard detailed
Duration15:19
Filing type10-K
PeriodAnnual 2023
IndustryHealthcare & Pharmaceuticals
Accession0000879169-24-000062

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in